Nimesulide
Specifications
51803-78-2CAS Number
257-431-4EC Number
N-(4-nitro-2-phenoxyphenyl)methanesulfonamideIUPAC Name
C13H12N2O5SChemical Formula
308.31 g/molMolecular Weight
nimesulide; 51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Aulin; R-805; Nimesulida; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; Nimesulidum; R 805; 4'-Nitro-2'-phenoxymethanesulfonanilide; DTXSID3037250; NSC-758412; V4TKW1454M; DTXCID1017250; CHEBI:44445; N-(4-nitro-2-(phenoxy)phenyl)methanesulfonamide; N-[4-nitro-2-(phenoxy)phenyl]methanesulfonamide; RefChem:6063; M01AX17; 257-431-4; Mesulid; Flogovital; Sulidene; Nimed; Nisulid; MFCD00079470; 4-Nitro-2-phenoxy-methanesulfonanilide; CHEMBL56367; MLS000069680; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; NCGC00015725-02; SMR000058484; CAS-51803-78-2; M02164; Antifloxil; Guaxan; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; NIM; Nimesulide [INN:BAN]; SR-01000000218; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; UNII-V4TKW1454M; Aldoron; Nimedex; Orthobid; CCRIS 8225; Nimesulide CRS; Nise Gel; Prestwick_618; Nimesulide (Standard); Spectrum_001577; NIMESULIDE [MI]; Nimesulide (JAN/INN); NIMESULIDE [INN]; NIMESULIDE [JAN]; Opera_ID_1247; Prestwick0_000194; Prestwick1_000194; Prestwick2_000194; Prestwick3_000194; Spectrum2_001541; Spectrum3_001576; Spectrum4_000178; Spectrum5_000964; Lopac-N-1016; N-(4-nitro-2-phenoxy-phenyl)methanesulfonamide; NIMESULIDE [MART.]; NIMESULIDE [WHO-DD]; Lopac0_000855; SCHEMBL24882; BSPBio_000147; BSPBio_001103; BSPBio_003112; KBioGR_000443; KBioGR_000695; KBioSS_000443; KBioSS_002057; MLS001148268; DivK1c_000693; SPECTRUM1503231; SPBio_001382; SPBio_002068; BPBio1_000163; GTPL7401; NIM-03; Nimesulide - Bio-X trade mark; orb1224837; orb1309658; NIMESULIDE [EP IMPURITY]; Nimesulide R&D Working Standard; SCHEMBL29393272; BCBcMAP01_000034; HMS502C15; HY-B0363R; KBio1_000693; KBio2_000443; KBio2_002057; KBio2_003011; KBio2_004625; KBio2_005579; KBio2_007193; KBio3_000825; KBio3_000826; KBio3_002612; NIMESULIDE [EP MONOGRAPH]; NINDS_000693; Bio2_000382; Bio2_000862; HMS1362G05; HMS1568H09; HMS1792G05; HMS1922K17; HMS1990G05; HMS2089B14; HMS2095H09; HMS2234K19; HMS3262L11; HMS3269G17; HMS3371J19; HMS3403G05; HMS3414P09; HMS3649A04; HMS3655D13; HMS3678P07; HMS3712H09; HMS3884C22; HMS5080D19; Pharmakon1600-01503231; FDC18022; HY-B0363; MSK10036; Tox21_110207; Tox21_301850; Tox21_500855; 4-Nitro-2-phenoxymethane-sulfonamide; BDBM50056999; CCG-39319; EBC-26568; EI-287; NSC758412; s2040; AKOS015897356; Nimesulide for peak identification CRS; Tox21_110207_1; AC-4524; DB04743; FN26223; KS-1277; LP00855; NSC 758412; SDCCGSBI-0050831.P004; IDI1_000693; IDI1_002137; NCGC00015725-01; NCGC00015725-03; NCGC00015725-04; NCGC00015725-05; NCGC00015725-06; NCGC00015725-07; NCGC00015725-08; NCGC00015725-09; NCGC00015725-10; NCGC00015725-11; NCGC00015725-12; NCGC00015725-13; NCGC00015725-15; NCGC00015725-16; NCGC00015725-20; NCGC00015725-25; NCGC00015725-29; NCGC00021842-03; NCGC00021842-04; NCGC00021842-05; NCGC00021842-06; NCGC00021842-07; NCGC00021842-08; NCGC00255661-01; NCGC00261540-01; BN166246; Nimesulide 100 microg/mL in Acetonitrile; R805; SY108897; N-(4-Nitro-2-Phenoxy)Methanesulfonanilide; SBI-0050831.P003; DB-052029; AB00052332; EU-0100855; N0984; N3450; NS00006725; ST51015069; SW196785-3; T1133; (methylsulfonyl)(4-nitro-2-phenoxyphenyl)amine; D01049; D70376; N 1016; n-(4-nitro-2-phenoxyphenyl)methanesulphonamide; Q20994; AB00052332-16; AB00052332_17; AB00052332_18; EN300-7388636; SR-01000000218-2; SR-01000000218-6; SR-01000000218-7; BRD-K76775527-001-06-2; BRD-K76775527-001-18-7; BRD-K76775527-001-28-6; BRD-K76775527-001-29-4; BRD-K76775527-001-30-2; SR-01000000218-11; Nimesulide, European Pharmacopoeia (EP) Reference Standard; Nimesulide, Pharmaceutical Secondary Standard; Certified Reference Material; Nimesulide for peak identification, European Pharmacopoeia (EP) Reference Standard; 1364966-82-4Synonyms